US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioinvent International AB

3.29

0.0000

Volume:- -

Turnover:- -

Market Cap:216.40M

PE:-6.92

High:3.29

Open:3.29

Low:3.29

Close:3.29

52wk High:4.70

52wk Low:3.29

Shares:65.80M

Float Shares:32.82M

Volume Ratio:4.99

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4753

EPS(LYR):-0.4994

ROE:-30.60%

ROA:-19.02%

PB:2.52

PE(LYR):-6.59

Loading ...

Overview Company News Filings

Stifel Nicolaus Remains a Buy on BioInvent International AB (BOVNF)

Resolutions at BioInvent's Annual General Meeting 2025

ACCESS Newswire

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

ACCESS Newswire

BioInvent International AB: Interim Report January - March 2025

ACCESS Newswire

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

ACCESS Newswire

BioInvent International AB Publishes Annual Report 2024

ACCESS Newswire

BioInvent to Participate in Upcoming Investor Conferences

ACCESS Newswire

Notice to Annual General Meeting in BioInvent International AB

ACCESS Newswire

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

ACCESS Newswire

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BOVNF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOVNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOVNF\",,,,,undefined,":{"symbol":"BOVNF","market":"US","secType":"STK","nameCN":"Bioinvent International AB","latestPrice":3.2886,"timestamp":1756843200000,"preClose":3.2886,"halted":0,"volume":0,"delay":15,"floatShares":32815306,"shares":65804362,"eps":-0.475308,"marketStatus":"Pre-Mkt","change":0,"latestTime":"09-02 16:00:00 EDT Delay","open":3.2886,"high":3.2886,"low":3.2886,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.475308,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1756906200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":3.2886,"volumeRatio":4.989178601437883},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOVNF\",,,,,undefined,":{"symbol":"BOVNF","floatShares":32815306,"roa":"-19.02%","roe":"-30.60%","lyrEps":-0.499403,"volumeRatio":4.989178601437883,"shares":65804362,"dividePrice":0,"high":3.2886,"amplitude":0,"preClose":3.2886,"low":3.2886,"week52Low":3.2886,"pbRate":"2.52","psRate":"8.04","week52High":4.7,"institutionHeld":0,"latestPrice":3.2886,"eps":-0.475308,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.475308,"open":3.2886,"prevYearClose":4.7,"prevWeekClose":3.2886,"prevMonthClose":3.2886,"prevQuarterClose":3.2886,"fiveDayClose":3.2886,"twentyDayClose":3.2886,"sixtyDayClose":4.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOVNF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-24","symbol":"BOVNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1713931200000,"reportTimeType":"","actualEps":null},{"date":"2022-10-27","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666857600000,"name":null,"time":"Pre-Market","dateTimestamp":1666843200000,"actualEps":null},{"date":"2022-08-25","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1661414400000,"name":null,"time":"Pre-Market","dateTimestamp":1661400000000,"actualEps":null},{"date":"2022-04-27","symbol":"BOVNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651046400000,"name":null,"time":"Pre-Market","dateTimestamp":1651032000000,"actualEps":null},{"market":"US","date":"2020-12-14","symbol":"BOVNF","defaultRemindTime":1607956200000,"type":"split","dateTimestamp":1607922000000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOVNF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BOVNF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1743480000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOVNF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562594741","title":"Stifel Nicolaus Remains a Buy on BioInvent International AB (BOVNF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2562594741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562594741?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:55","pubTimestamp":1756299325,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst maintained a Buy rating on BioInvent International AB today and set a price target of SEK90.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-bioinvent-international-ab-bovnf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-bioinvent-international-ab-bovnf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BOVNF","LU0128526141.USD","BK4598","BK4135","BK4127","BK4590","AB","LU0029874061.USD","SF"],"gpt_icon":0},{"id":"2531768662","title":"Resolutions at BioInvent's Annual General Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531768662","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531768662?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:15","pubTimestamp":1745939700,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting  of BioInvent International AB   resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Laura Lassouw-Polman, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial year 2024 and decided that no dividend should be declared for the financial year 2024.The AGM resolved to adopt the Board's report regarding compensation pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.Last, the AGM authorized the Board to resolve on the issue of new shares, on one or several occasions during the period up to the ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resolutions-bioinvents-annual-general-meeting-151500582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BOVNF"],"gpt_icon":0},{"id":"2531557200","title":"BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2531557200","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531557200?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:15","pubTimestamp":1745921700,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of adults with relapsed or refractory mycosis fungoides and Sézary syndrome, subtypes of cutaneous T-cell lymphoma . Fast Track Designation  is intended to facilitate the development and review of drugs that treat serious conditions.About Phase 1/2a studyDuring the first part of the Phase 1/2a study  the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent  and in combination with the anti-PD-1 therapy pembrolizumab  are evaluated in patients with advanced solid tumors and T-cell lymphoma. The efficacy of BI-1808 as single agent is currently explored in the Phase 2a part of the tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-fast-track-101500462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FAST","BK4161","PR","SD","BK4213","BOVNF","CR"],"gpt_icon":0},{"id":"2531229051","title":"BioInvent International AB: Interim Report January - March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531229051","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531229051?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:20","pubTimestamp":1745907600,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International . \"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year.\"- Martin Welschof CEO of BioInvent. Phase 1 data of the company's second anti-TNFR2 antibody BI-1910 as monotherapy for the treatment of solid tumors. BioInvent achieved ISO 26000 Verification, highlighting commitment to ESG and transparency. Composition of matter patent for the lead anti-TNFR2 antibody BI-1808 granted in Japan. It also covers the use of the antibody in the treatment of cancer. About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-international-ab-interim-report-062000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["R","BK4135","BK4598","AB","BK4022","BK4232","LU0128526141.USD","BK4590","BOVNF","LU0029874061.USD","BK4139"],"gpt_icon":0},{"id":"2525248895","title":"BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525248895","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525248895?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:15","pubTimestamp":1744110900,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's  initiation of Phase 3 clinical trial of mezagitamab , identified from BioInvent's proprietary n-CoDeR antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia .\"We are excited to see mezagitamab progress into Phase 3 trials, marking a significant step for Takeda and our n-CoDeR platform,\" said Martin Welschof, Chief Executive Officer of BioInvent. \"This milestone not only validates the consistent high quality of drug candidates identified from our n-CoDeR antibody library, but it also highlights the success of our out-licensing strategy and its ability to drive real-world impact t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-milestone-payment-takeda-111500286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XOMA","BOVNF","BK4139","BK4007","TAK","BK4199","ITP"],"gpt_icon":0},{"id":"2524327139","title":"BioInvent International AB Publishes Annual Report 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2524327139","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524327139?lang=en_us&edition=fundamental","pubTime":"2025-04-04 16:20","pubTimestamp":1743754800,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 4, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2024 has been published. The Annual Report is attached to this press release in pdf format and is available on the company's website www.bioinvent.com .About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-international-ab-publishes-annual-082000529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AB","BK4139","BK4135","BK4598","BOVNF","BK4590","LU0029874061.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2524167450","title":"BioInvent to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524167450","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524167450?lang=en_us&edition=fundamental","pubTime":"2025-04-01 17:20","pubTimestamp":1743499200,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / April 1, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that during April, the Company management team will participate in the following upcoming investor conferences:. Van Lanschot Kempen Life Sciences ConferenceFormat: One-on-one meetingsDate: April 2Location: Amsterdam, The Netherlands. Stifel Virtual Targeted Oncology ForumFormat: Corporate presentation and one-on-one meetings Date: April 8-9. Corporate presentation April 9 at 11:30 am EDT Location: Virtual. About BioInventBioInvent International AB  is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-participate-upcoming-investor-conferences-092000546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BOVNF"],"gpt_icon":0},{"id":"2522010593","title":"Notice to Annual General Meeting in BioInvent International AB","url":"https://stock-news.laohu8.com/highlight/detail?id=2522010593","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522010593?lang=en_us&edition=fundamental","pubTime":"2025-03-25 17:20","pubTimestamp":1742894400,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / March 25, 2025 / BioInvent International  The shareholders of BioInvent International AB , Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April 2025 at Elite Hotel Ideon on Scheelevgen 27 in Lund, Sweden.A shareholder who wishes to attend the meeting room or who wishes to exercise its voting rights by voting in advance by post must be recorded in the share register maintained by Euroclear Sweden AB , as of 17 April 2025; and must. If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder must be issued for the representative. Forms of power of attorney are available on the company's website, www.bioinvent.com . If the shareholder is a legal entity, a certificate of incorporation, or corresponding authorization document, must be attached. The power of attorney together with any registration certificate and other authorization documents should be sent t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/notice-annual-general-meeting-bioinvent-092000234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0128526141.USD","BK4135","LU0029874061.USD","BK4139","BOVNF","BK4590","BK4598","AB"],"gpt_icon":0},{"id":"2521200024","title":"BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2521200024","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521200024?lang=en_us&edition=fundamental","pubTime":"2025-03-21 15:20","pubTimestamp":1742541600,"startTime":"0","endTime":"0","summary":"BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that one of the company's lead program; BI-1808 as monotherapy in Cutaneous T Cell Lymphoma  will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California.The data, previously disclosed in a press release in September 2024, will be featured in a poster presentation highlighting the early efficacy of BI-1808 monotherapy in the ongoing Phase 2a dose expansion study in CTCL. So far three partial responses  and one stable disease  out of four evaluable patients have been reported. The Company anticipates reporting additional data from the study in mid-2025.BI-1808, a first-in-class anti-TNFR2 antibody, was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration  for the treatment of TCL.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-anti-tnfr2-antibody-bi-072000423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4179","BOVNF","BK4213","SD","CR","PR","FET","BK4161"],"gpt_icon":0},{"id":"2520107816","title":"BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2520107816","media":"ACCESS Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520107816?lang=en_us&edition=fundamental","pubTime":"2025-03-20 15:20","pubTimestamp":1742455200,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  for BI-1808, a first-in-class anti-TNFR2 antibody for the treatment of T-cell Lymphoma .\"We are excited to receive the FDA's Orphan Drug Designation for the treatment of TCL. This designation along with the recently announced positive Phase 2a data in CTCL reinforces our continued progress and commitment to developing BI-1808 as a potential novel class of immunomodulatory agents for TCL\", said Martin Welschof, Chief Executive Officer of BioInvent. \"We look forward to working closely with the regulatory agencies to accelerate the development of BI-1808 and bring this innovative treatment to patients who are in great need of new treatment options.\". About the Phase 1/2a studyDur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-orphan-drug-072000957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","BOVNF","PR","BK4139","ODD","CR","BK4161","SD","BK4213"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}